IL15 and congenital rubella syndrome: Other notable interactions included canakinumab (IL1B inhibitor, score: 2.55) and ordesekimab (IL15 inhibitor, score: 3.72), both of which are known to modulate inflammatory responses and may have potential applications in mitigating CRS.